Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 10/2018

01-09-2018 | Original Article

Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours

Authors: Marie Paquet, Mathieu Gauthé, Jules Zhang Yin, Valérie Nataf, Ophélie Bélissant, Philippe Orcel, Christian Roux, Jean-Noël Talbot, Françoise Montravers

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2018

Login to get access

Abstract

Purpose

Oncogenic osteomalacia is an endocrine disorder induced by small benign tumours (TIO) producing excessive fibroblast growth factor-23 (FGF23). The only way of curing oncogenic osteomalacia is surgical resection of the culprit TIO, which is extremely difficult to detect using conventional imaging modalities due to its small size and variable location in the body. Since TIO frequently overexpress somatostatin receptors, a clinical utility of SPECT or PET with radiolabelled somatostatin analogues has been reported. Among them, 68Ga-DOTA-TOC has recently been granted a marketing authorization, facilitating its routine application. We report here the results of the first series evaluating the diagnostic performance of 68Ga-DOTA-TOC PET/CT in detecting TIO and its impact on patient management.

Methods

68Ga-DOTA-TOC PET/CT and clinical and imaging data from 15 patients with clinical and biochemical signs of oncogenic osteomalacia were retrospectively reviewed. The 68Ga-DOTA-TOC PET/CT findings were compared with the results of post-surgical pathology and clinical and biochemical follow-up.

Results

68Ga-DOTA-TOC PET/CT resulted in the detection of one focus suspicious for TIO in nine of 15 patients (60%), and a tumour was surgically removed in eight. Post-operative pathology confirmed a TIO in those eight patients whose symptoms diminished promptly and biochemical anomalies resolved. 68Ga-DOTA-TOC PET/CT sensitivity, specificity and accuracy were 73%, 67% and 71%, respectively. 68Ga-DOTA-TOC PET/CT findings affected patient management in 67% of cases. In particular, 68Ga-DOTA-TOC PET/CT was able to detect the TIO with a negative or a false-positive result of a previous 111In-pentetreotide SPECT/CT in 5/8 patients (63%) or a previous FDG PET/CT in 7/11 patients (64%). No close relationship was found between the positivity of 68Ga-DOTA-TOC PET/CT and the serum level of a biochemical marker. However, a true-positive result of 68Ga-DOTA-TOC PET/CT was obtained in only one patient with a non-elevated serum level of FGF23.

Conclusion

68Ga-DOTA-TOC PET/CT is an accurate imaging modality in the detection of TIO; in particular, it is worthwhile after failure of somatostatin receptor SPECT(/CT) or FDG PET/CT.
Literature
1.
Carpenter TO. Oncogenic osteomalacia—a complex dance of factors. N Engl J Med. 2003;348:1705–8.CrossRefPubMed
2.
Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1–30.CrossRefPubMed
3.
Nelson AE, Bligh RC, Mirams M, Gill A, Au A, Clarkson A, et al. Clinical case seminar: fibroblast growth factor 23: a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab. 2003;88:4088–94.CrossRefPubMed
4.
Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348(17):1656–63.CrossRefPubMed
5.
Ledford CK, Zelenski NA, Cardona DM, Brigman BE, Eward WC. The phosphaturic mesenchymal tumor: why is definitive diagnosis and curative surgery often delayed? Clin Orthop. 2013;471:3618–25.CrossRefPubMed
6.
7.
Chong WH, Andreopoulou P, Chen CC, Reynolds J, Guthrie L, Kelly M, et al. Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J Bone Miner Res. 2013;28:1386–98.CrossRefPubMedPubMedCentral
8.
Chong WH, Yavuz S, Patel SM, Chen CC, Collins MT. The importance of whole body imaging in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2011;96:3599–600.CrossRefPubMedPubMedCentral
9.
Houang M, Clarkson A, Sioson L, Elston MS, Clifton-Bligh RJ, Dray M, et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum Pathol. 2013;44(12):2711–8.CrossRefPubMed
10.
Clifton-Bligh RJ, Hofman MS, Duncan E, Sim I-W, Darnell D, Clarkson A, et al. Improving diagnosis of tumor-induced osteomalacia with gallium-68 DOTATATE PET/CT. J Clin Endocrinol Metab. 2013;98:687–94.CrossRefPubMed
11.
Jan de Beur SM, Streeten EA, Civelek AC, EF MC, Uribe L, Marx SJ, et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet Lond Engl. 2002;359:761–3.CrossRef
12.
13.
Nguyen BD, Wang EA. Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia. Clin Nucl Med. 1999;24:130–1.CrossRefPubMed
14.
Krausz Y, Freedman N, Rubinstein R, Lavie E, Orevi M, Tshori S, et al. 68Ga-DOTA-NOC PET/CT imaging of neuroendocrine tumors: comparison with 111In-DTPA-octreotide (OctreoScan®). Mol Imaging Biol. 2011;13:583–93.CrossRefPubMed
15.
Deppen SA, Blume J, Bobbey AJ, Shah C, Graham MM, Lee P, et al. 68Ga-DOTATATE compared with 111In-DTPA-octreotide and conventional imaging for pulmonary and gastroenteropancreatic neuroendocrine tumors: a systematic review and meta-analysis. J Nucl Med. 2016;57:872–8.CrossRefPubMedPubMedCentral
16.
Graham MM, Gu X, Ginader T, Breheny P, Sunderland JJ. 68Ga-DOTATOC imaging of neuroendocrine tumors: a systematic review and metaanalysis. J Nucl Med. 2017;58:1452–8.CrossRefPubMed
17.
Hesse E, Moessinger E, Rosenthal H, Laenger F, Brabant G, Petrich T, et al. Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res. 2007;22:158–62.CrossRefPubMed
18.
Haeusler G, Freilinger M, Dominkus M, Egerbacher M, Amann G, Kolb A, et al. Tumor-induced hypophosphatemic rickets in an adolescent boy - clinical presentation, diagnosis, and histological findings in growth plate and muscle tissue. J Clin Endocrinol Metab. 2010;95:4511–7.CrossRefPubMed
19.
Maybody M, Grewal RK, Healey JH, Antonescu CR, Fanchon L, Hwang S, et al. Ga-68 DOTATOC PET/CT-guided biopsy and cryoablation with autoradiography of biopsy specimen for treatment of tumor-induced osteomalacia. Cardiovasc Intervent Radiol. 2016;39:1352–7.CrossRefPubMedPubMedCentral
20.
Kawai S, Ariyasu H, Furukawa Y, Yamamoto R, Uraki S, Takeshima K, et al. Effective localization in tumor-induced osteomalacia using 68Ga-DOTATOC-PET/CT, venous sampling and 3T-MRI. Endocrinol Diabetes Metab Case Rep. 2017;2017
21.
Michaud L, Balogova S, Burgess A, Ohnona J, Huchet V, Kerrou K, et al. A pilot comparison of 18F-fluorocholine PET/CT, ultrasonography and 123I/99mTc-sestaMIBI dual-phase dual-isotope scintigraphy in the preoperative localization of hyperfunctioning parathyroid glands in primary or secondary hyperparathyroidism: influence of thyroid anomalies. Medicine (Baltimore). 2015;94(41):e1701.CrossRef
22.
Jiang Y, Xia W, Xing X, Silva BC, Li M, Wang O, et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J Bone Miner Res. 2012;27:1967–75.CrossRefPubMed
23.
Johnbeck CB, Knigge U, Kjær A. PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature. Future Oncol. 2014;10(14):2259–77.CrossRefPubMed
24.
Jing H, Li F, Zhuang H, Wang Z, Tian J, Xing X, et al. Effective detection of the tumors causing osteomalacia using [Tc-99m]-HYNIC-octreotide (99mTc-HYNIC-TOC) whole body scan. Eur J Radiol. 2013;82:2028–34.CrossRefPubMed
25.
Jadhav S, Kasaliwal R, Lele V, Rangarajan V, Chandra P, Shah H, et al. Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET/CT vs somatostatin receptor-based functional scans: a series of nine patients. Clin Endocrinol. 2014;81:31–7.CrossRef
26.
Dong C, Zhao H, Yang S, Shi J, Huang J, Cui L, et al. 99mTc-labeled dimeric octreotide peptide: a radiotracer with high tumor uptake for single-photon emission computed tomography imaging of somatostatin receptor subtype 2-positive tumors. Mol Pharm. 2013;10(8):2925–33.CrossRefPubMed
27.
Breer S, Brunkhorst T, Beil FT, Peldschus K, Heiland M, Klutmann S, et al. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT. Bone. 2014;64:222–7.CrossRefPubMed
28.
Agrawal K, Bhadada S, Mittal BR, Shukla J, Sood A, Bhattacharya A, et al. Comparison of 18F-FDG and 68Ga DOTATATE PET/CT in localization of tumor causing oncogenic osteomalacia. Clin Nucl Med. 2015;40:e6–10.CrossRefPubMed
29.
Ho CL. Ga68-DOTA peptide PET/CT to detect occult mesenchymal tumor-inducing osteomalacia: a case series of three patients. Nucl Med Mol Imaging. 2015;49:231–6.CrossRefPubMedPubMedCentral
30.
El-Maouche D, Sadowski SM, Papadakis GZ, Guthrie L, Cottle-Delisle C, Merkel R, et al. 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J Clin Endocrinol Metab. 2016;101:3575–81.CrossRefPubMedPubMedCentral
31.
Zhang J, Zhu Z, Zhong D, Dang Y, Xing H, Du Y, et al. 68Ga DOTATATE PET/CT is an accurate imaging modality in the detection of culprit tumors causing osteomalacia. Clin Nucl Med. 2015;40:642–6.CrossRefPubMed
32.
Singh D, Chopra A, Ravina M, Kongara S, Bhatia E, Kumar N, et al. Oncogenic osteomalacia: role of Ga-68 DOTANOC PET/CT scan in identifying the culprit lesion and its management. Br J Radiol. 2017;90:20160811.CrossRefPubMedPubMedCentral
33.
Bhavani N, Reena Asirvatham A, Kallur K, Menon AS, Pavithran PV, Nair V, et al. Utility of gallium-68 DOTANOC PET/CT in the localization of tumour-induced osteomalacia. Clin Endocrinol. 2016;84:134–40.CrossRef
34.
Lichtenauer-Kaligis EG, Dalm VA, Oomen SP, Mooij DM, van Hagen PM, Lamberts SW, et al. Differential expression of somatostatin receptor subtypes in human peripheral blood mononuclear cell subsets. Eur J Endocrinol. 2004;150(4):565–77.CrossRefPubMed
35.
Dupond JL, Mahammedi H, Prié D, Collin F, Gil H, Blagosklonov O, et al. Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Bone. 2005;36:375–8.CrossRefPubMed
36.
Malhotra G, Agrawal A, Jambhekar NA, Sarathi V, Jagtap V, Agarwal MG, et al. Interesting image. The search for primary tumor in a patient with oncogenic osteomalacia: F-18 FDG PET resolves the conundrum. Clin Nucl Med. 2010;35:896–8.CrossRefPubMed
37.
Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, et al. Dual somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017;7(5):1149–58.CrossRefPubMedPubMedCentral
Metadata
Title
Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET/CT for detecting osteomalacia-associated tumours
Authors
Marie Paquet
Mathieu Gauthé
Jules Zhang Yin
Valérie Nataf
Ophélie Bélissant
Philippe Orcel
Christian Roux
Jean-Noël Talbot
Françoise Montravers
Publication date
01-09-2018
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2018
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-018-3971-x

Other articles of this Issue 10/2018

European Journal of Nuclear Medicine and Molecular Imaging 10/2018 Go to the issue

Original Article

18F-Fluorocholine PET/CT in the assessment of primary hyperparathyroidism compared with 99mTc-MIBI or 99mTc-tetrofosmin SPECT/CT: a prospective dual-centre study in 100 patients

Guidelines

Clinical indications, image acquisition and data interpretation for white blood cells and anti-granulocyte monoclonal antibody scintigraphy: an EANM procedural guideline

Editorial

Molecular imaging and molecular diagnostics: two sides of the same coin?

Reply

Reply to the letter

Short Communication

Post-treatment positron emission tomography-computed tomography is highly predictive of outcome in Plasmablastic lymphoma

Original Article

Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma